Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Pacing Clin Electrophysiol ; 42(10): 1355-1364, 2019 10.
Article in English | MEDLINE | ID: mdl-31433064

ABSTRACT

BACKGROUND: Transvenous lead extraction (TLE) may be performed by superior approach using the original implant vein or via a femoral approach; however, limited comparative data exists. We compare outcomes between femoral versus nonfemoral TLE approaches and determine predictors of bailout transfemoral lead extraction in patients undergoing initial TLE via the original implant vein by a superior approach. METHODS: All consecutive TLEs between October 2000 and March 2018 were prospectively collected (n = 1052). Patients were dichotomized into femoral (n = 118) and nonfemoral (n = 934) groups. RESULTS: Demographics were balanced between femoral vs nonfemoral groups. Patients in the femoral group had significantly higher mean lead dwell times (11.6 ± 9.7 vs 6.6 ± 6.6 years, P < .001), mean number of leads extracted (2.7 ± 1.3 vs 2.0 ± 1.0, P < .001), 30-day procedure related major complications (including deaths) (8.5% vs 1.1%, P < .001) and emergency thoracotomy rates (4.2% vs 0.7%, P = .007). All-cause 30-day mortality rates were similar between groups (3.4% vs 2.0%, P = .315). Prolonged lead dwell time and increased number of leads extracted were predictive of a bailout transfemoral approach at multivariable analysis. CONCLUSION: Femoral approach TLE is associated with increased risk of 30-day procedure related major complications but not 30-day all-cause mortality. Prolonged lead dwell time and increased number of leads extracted are independent predictors for bailout transfemoral lead extraction. Such patients should be considered high risk of major complications and performed by high-volume lead extraction centers with experience in multiple approaches and techniques including experience with transfemoral lead extraction.


Subject(s)
Defibrillators, Implantable/adverse effects , Device Removal , Pacemaker, Artificial/adverse effects , Aged , Equipment Design , Equipment Failure , Femoral Vein , Humans , Middle Aged , Prospective Studies , Registries , Risk Factors , Time Factors
2.
Heart Fail Rev ; 24(1): 41-54, 2019 01.
Article in English | MEDLINE | ID: mdl-30143910

ABSTRACT

Heart failure is a complex clinical syndrome associated with a significant morbidity and mortality burden. Reductions in left ventricular (LV) function trigger adaptive mechanisms, leading to structural changes within the LV and the potential development of dyssynchronous ventricular activation. This is the substrate targeted during cardiac resynchronisation therapy (CRT); however, around 30-50% of patients do not experience benefit from this treatment. Non-response occurs as a result of pre-implant, peri-implant and post implant factors but the technical constraints of traditional, transvenous epicardial CRT mean they can be challenging to overcome. In an effort to improve response, novel alternative methods of CRT delivery have been developed and of these endocardial pacing, where the LV is stimulated from inside the LV cavity, appears the most promising.


Subject(s)
Cardiac Resynchronization Therapy/adverse effects , Cardiac Resynchronization Therapy/methods , Heart Failure/therapy , Ventricular Dysfunction, Left/therapy , Endocardium/metabolism , Female , Heart Failure/physiopathology , Humans , Male , Pericardium/metabolism , Sex Factors , Treatment Outcome , Ventricular Dysfunction, Left/physiopathology
3.
Pacing Clin Electrophysiol ; 42(1): 73-84, 2019 01.
Article in English | MEDLINE | ID: mdl-30411817

ABSTRACT

BACKGROUND: Transvenous lead extraction (TLE) may be necessary due to infective and noninfective indications. We aim to identify predictors of 30-day mortality and risk factors between infective versus noninfective groups and systemic versus local infection subgroups. METHODS: A total of 925 TLEs between October 2000 and December 2016 were prospectively collected and dichotomized (infective group n = 505 vs noninfective group n = 420 and systemic infection n = 164 vs local infection n = 341). RESULTS: All-cause major complication including deaths was significantly higher (5.1%, n = 26 vs 1.2%, n = 5, P = 0.001) as well as 30-day mortality (4.0%, n = 20 vs 0.2%, n = 1, P < 0.001) in the infective group compared to the noninfective group. Both subgroups (systemic vs local infection) were balanced for demographics. All-cause major complication including deaths was significantly higher (9.1%, n = 15 vs 3.2%, n = 11, P = 0.008) as well as all-cause 30-day mortality (7.9%, n  = 13 vs 2.1%, n = 7, P = 0.003) in the systemic infection subgroup compared to the local infection subgroup. CONCLUSION: Patients undergoing TLE for infective indications are at greater risk of 30-day all-cause mortality compared to noninfective patients. Patients undergoing TLE for systemic infective indications are at greater risk of 30-day all-cause mortality compared to patients with local infection. Renal impairment, systemic infection, and elevated preprocedure C-reactive protein are independent predictors of 30-day all-cause mortality in patients undergoing TLE for an infective indication.


Subject(s)
Defibrillators, Implantable/adverse effects , Device Removal/methods , Pacemaker, Artificial/adverse effects , Prosthesis-Related Infections/etiology , Prosthesis-Related Infections/mortality , Aged , Cause of Death , Device Removal/adverse effects , Female , Humans , Male , Predictive Value of Tests , Prospective Studies , Risk Assessment , Risk Factors
4.
Int J Cardiol ; 257: 131-136, 2018 04 15.
Article in English | MEDLINE | ID: mdl-29506684

ABSTRACT

AIMS: The 2014 National Institute of Clinical Excellence (NICE) guidelines on the management of acute heart failure recommended using a plasma NT-proBNP threshold of 300pg/ml to assist in ruling out the diagnosis of heart failure (HF), updating previous guidelines recommending using a threshold of 400pg/ml. NICE based their recommendations on 6 studies performed in other countries. This study sought to determine the diagnostic and economic implications of using these thresholds in a large unselected UK population. METHODS: Patient and clinical demographics were recorded for all consecutive suspected HF patients over 12months, as well as clinical outcomes including time to HF hospitalisation and time to death (follow up 15.8months). RESULTS: Of 1995 unselected patients admitted with clinically suspected HF, 1683 (84%) had a NTproBNP over the current NICE recommended threshold, of which 35% received a final diagnosis of HF. Lowering the threshold from 400 to 300pg/ml would have involved screening an additional 61 patients and only would have identified one new patient with HF (sensitivity 0.985, NPV 0.976, area under the curve (AUC) at 300pg/ml 0.67; sensitivity 0.983, NPV 0.977, AUC 0.65 at 400pg/ml). The economic implications of lowering the threshold would have involved additional costs of £42,842.04 (£702.33 per patient screened, or £ 42,824.04 per new HF patient). CONCLUSION: Applying the recent updated NICE guidelines to an unselected real world population increases the AUC but would have a significant economic impact and only identified one new patient with heart failure.


Subject(s)
Cost-Benefit Analysis/methods , Heart Failure/economics , Hospitalization/economics , Natriuretic Peptide, Brain/economics , Peptide Fragments/economics , Practice Guidelines as Topic/standards , Biomarkers/blood , Heart Failure/blood , Heart Failure/diagnosis , Hospitalization/trends , Humans , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Reference Standards
5.
Am J Cardiol ; 119(9): 1450-1455, 2017 05 01.
Article in English | MEDLINE | ID: mdl-28267963

ABSTRACT

Echocardiography-derived measurements of maximum left ventricular (LV) wall thickness are important for both the diagnosis and risk stratification of hypertrophic cardiomyopathy (HC). Cardiac magnetic resonance (CMR) imaging is increasingly being used in the assessment of HC; however, little is known about the relation between wall thickness measurements made by the 2 modalities. We sought to compare measurements made with echocardiography and CMR and to assess the impact of any differences on risk stratification using the current European Society of Cardiology guidelines. Maximum LV wall thickness measurements were recorded on 50 consecutive patients with HC. Sixty-nine percent of LV wall thickness measurements were recorded with echocardiography, compared with 69% from CMR (p <0.001). There was poor agreement on the location of maximum LV wall thickness; weighted-Cohen's κ 0.14 (p = 0.036) and maximum LV wall thicknesses were systematically higher with echocardiography than with CMR (mean 19.1 ± 0.4 mm vs 16.5 ± 0.3 mm, p <0.01, respectively); Bland-Altman bias 2.6 mm (95% confidence interval -9.8 to 4.6). Interobserver variability was lower for CMR (R2 0.67 echocardiography, R2 0.93 CMR). The mean difference in 5-year sudden cardiac death (SCD) risk between echocardiography and CMR was 0.49 ± 0.45% (p = 0.37). When classifying patients (low, intermediate, or high risk), 6 patients were reclassified when CMR was used instead of echocardiography to assess maximum LV wall thickness. These findings suggest that CMR measurements of maximum LV wall thickness can be cautiously used in the current European Society of Cardiology risk score calculations, although further long-term studies are needed to confirm this.


Subject(s)
Cardiomyopathy, Hypertrophic/diagnostic imaging , Death, Sudden, Cardiac/epidemiology , Heart Ventricles/diagnostic imaging , Adult , Aged , Cardiomyopathy, Hypertrophic/complications , Cardiomyopathy, Hypertrophic/pathology , Death, Sudden, Cardiac/etiology , Echocardiography , Female , Heart Ventricles/pathology , Humans , Magnetic Resonance Imaging , Magnetic Resonance Imaging, Cine , Male , Middle Aged , Organ Size , Risk Assessment
SELECTION OF CITATIONS
SEARCH DETAIL
...